GMP-compliant iPS cell lines show widespread plasticity in a new set of differentiation workflows for cell replacement and cancer immunotherapy
This article explores the creation of Good Manufacturing Practice-compliant workflows for producing induced pluripotent stem cells and explores the strict quality and consistency standards set by Good Manufacturing Practice regulations. It also outlines a new protocols for the differentiation of iPSC lines into cell types, including retinal pigment epithelial cells, mesenchymal stromal cells, cardiomyocytes and immune cells like macrophages, T cells and natural killer cells.
This content is part of the RegMedNet Spotlight on iPSCs. Click here to view the full feature and discover expert insights on this.
This content was provided by Catalent.
